Cell Reports (May 2024)

The Janus kinase 1 is critical for pancreatic cancer initiation and progression

  • Hridaya Shrestha,
  • Patrick D. Rädler,
  • Rayane Dennaoui,
  • Madison N. Wicker,
  • Nirakar Rajbhandari,
  • Yunguang Sun,
  • Amy R. Peck,
  • Kerry Vistisen,
  • Aleata A. Triplett,
  • Rafic Beydoun,
  • Esta Sterneck,
  • Dieter Saur,
  • Hallgeir Rui,
  • Kay-Uwe Wagner

Journal volume & issue
Vol. 43, no. 5
p. 114202

Abstract

Read online

Summary: Interleukin-6 (IL-6)-class inflammatory cytokines signal through the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) pathway and promote the development of pancreatic ductal adenocarcinoma (PDAC); however, the functions of specific intracellular signaling mediators in this process are less well defined. Using a ligand-controlled and pancreas-specific knockout in adult mice, we demonstrate in this study that JAK1 deficiency prevents the formation of KRASG12D-induced pancreatic tumors, and we establish that JAK1 is essential for the constitutive activation of STAT3, whose activation is a prominent characteristic of PDAC. We identify CCAAT/enhancer binding protein δ (C/EBPδ) as a biologically relevant downstream target of JAK1 signaling, which is upregulated in human PDAC. Reinstating the expression of C/EBPδ was sufficient to restore the growth of JAK1-deficient cancer cells as tumorspheres and in xenografted mice. Collectively, the findings of this study suggest that JAK1 executes important functions of inflammatory cytokines through C/EBPδ and may serve as a molecular target for PDAC prevention and treatment.

Keywords